Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
about
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia.New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
P2860
Q39453691-13382E70-CF37-43F9-8AD2-90F969DDBD6BQ47130329-CB37F701-CEC0-4EC4-8BEA-074B56CC2CC0Q47279052-71D53FE8-033C-49CF-A5D1-B68DE8C06331Q47419614-9BDC475F-0A23-4728-930E-127971AADF6BQ48254766-49C59670-789F-4FCC-8566-A53B25005ACFQ50047295-EF583447-89DA-406F-A0CF-44F0ACCCECBFQ55021969-EBBC0849-4526-4B08-A250-8A5C23A66605
P2860
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Design and rationale of the OD ...... a at high cardiovascular risk.
@ast
Design and rationale of the OD ...... a at high cardiovascular risk.
@en
type
label
Design and rationale of the OD ...... a at high cardiovascular risk.
@ast
Design and rationale of the OD ...... a at high cardiovascular risk.
@en
prefLabel
Design and rationale of the OD ...... a at high cardiovascular risk.
@ast
Design and rationale of the OD ...... a at high cardiovascular risk.
@en
P2093
P2860
P1476
Design and rationale of the OD ...... ia at high cardiovascular risk
@en
P2093
Bertrand Cariou
Dirk Müller-Wieland
Francisco J Tinahones
Helen M Colhoun
Jaman Maroni
Kausik K Ray
Lawrence A Leiter
Lisa Aurand
Maja Bujas-Bobanovic
Robert R Henry
P2860
P2888
P356
10.1186/S12933-017-0552-4
P407
P577
2017-05-25T00:00:00Z
P6179
1085597579